v3.26.1
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 22, 2026
Jun. 30, 2026
Dec. 31, 2025
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Oct. 01, 2025
Dec. 31, 2024
Goodwill [Line Items]                  
Asset impairments   $ 9,000,000   $ 0 $ 9,000,000 $ 0      
Finite-lived intangible assets   2,381,000,000 $ 2,845,000,000   2,381,000,000   $ 2,845,000,000    
Goodwill, impairment loss         1,426,000,000   145,000,000    
Goodwill   9,793,000,000 $ 11,271,000,000   9,793,000,000   $ 11,271,000,000   $ 11,087,000,000
Accumulated goodwill impairment charges   7,068,000,000     7,068,000,000        
Vision Care, Pharmaceuticals and Surgical                  
Goodwill [Line Items]                  
Fair value of reporting value, greater than its carrying value       25.00%   25.00%      
Goodwill, impairment loss           $ 0      
Vision Care, Pharmaceuticals and Surgical | Maximum                  
Goodwill [Line Items]                  
Reporting unit, impairment test, long-term growth rate       3.00%   3.00%      
Reporting unit, impairment test, estimated cash flows, discount rate       11.50%   11.50%      
Vision Care, Pharmaceuticals and Surgical | Minimum                  
Goodwill [Line Items]                  
Reporting unit, impairment test, estimated cash flows, discount rate       10.00%   10.00%      
Salix Reporting Unit                  
Goodwill [Line Items]                  
Reporting unit, impairment test, long-term growth rate               2.50%  
Reporting unit, impairment test, estimated cash flows, discount rate     9.50%       9.50% 9.75%  
Goodwill, impairment loss $ 1,426,000,000                
Goodwill   1,733,000,000 $ 3,159,000,000   1,733,000,000   $ 3,159,000,000    
Salix Reporting Unit | Bausch + Lomb                  
Goodwill [Line Items]                  
Goodwill, impairment loss     $ 0            
Neurology Reporting Unit                  
Goodwill [Line Items]                  
Reporting unit, impairment test, long-term growth rate     (2.50%)       (2.50%)    
Reporting unit, impairment test, estimated cash flows, discount rate     9.75%       9.75%    
Fair value of reporting value, greater than its carrying value     100.00%       100.00%    
Goodwill, impairment loss     $ 0            
Goodwill     $ 1,170,000,000       $ 1,170,000,000    
Generics Reporting Unit                  
Goodwill [Line Items]                  
Reporting unit, impairment test, estimated cash flows, discount rate     8.75%       8.75%    
Goodwill, impairment loss     $ 145,000,000            
Goodwill     $ 82,000,000       $ 82,000,000    
Xifaxan Branded Products                  
Goodwill [Line Items]                  
Finite-lived intangible assets   $ 808,000,000     $ 808,000,000        
Finite lived intangible assets, useful life   18 months     18 months